相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome
Byambaa Enkhmaa et al.
CLINICAL ENDOCRINOLOGY (2016)
Lipoprotein (a) measurements for clinical application
Santica M. Marcovina et al.
JOURNAL OF LIPID RESEARCH (2016)
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Michel Farnier et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a)
Margaret R. Diffenderfer et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in Africane-Americans
Byambaa Enkhmaa et al.
ATHEROSCLEROSIS (2014)
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial
C. Hernandez et al.
DIABETES & METABOLISM (2011)
Association of Lp-PLA2 activity with allele-specific Lp(a) levels in a bi-ethnic population
Byambaa Enkhmaa et al.
ATHEROSCLEROSIS (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Apolipoprotein(a) Isoforms and the Risk of Vascular Disease Systematic Review of 40 Studies Involving 58,000 Participants
Sebhat Erqou et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population
Pia R. Kamstrup et al.
CIRCULATION (2008)
Lipoprotein(a) An elusive cardiovascular risk factor
L Berglund et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk
S Gonbert et al.
ATHEROSCLEROSIS (2002)
High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men
F Paultre et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
